Developer docs
API playgroundTry for free, no card

Search company profiles

Wision A.I.

Full company profile

uuid00031se

Namestring
Wision A.I.
Legal namestring
Wision A.I.
Websiteurl
wision.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Wision A.I. is a Shanghai-based medical device software company founded in 2016 that develops computer-aided diagnosis (CAD) algorithms for optical clinical imaging, with a stated focus on solving diagnostic problems using small datasets rather than the prevailing big-data paradigm. Its commercial portfolio consists of two flagship products: EndoScreener, a real-time AI-aided detection (CADe) tool that flags potential lesions and polyps during colonoscopy, and PathoCruz, which localizes cancerous regions in whole-slide histopathology images; a 3D reconstruction add-on, PathoCruz 3D, extends the pathology line into tumor spatial visualization. Underlying both products is a deep-learning computer-vision pipeline with an articulated mathematical-rigor orientation toward limited training data.

The company monetizes as a regulated medical device vendor, not as a SaaS or platform play. Its products have been cleared as medical devices across the three principal regulatory regimes — FDA 510(k) (K211326), CE-MDR Class II (the first colonoscopy CADe clearance under MDR 2017/745), and NMPA Class III via China's Innovative Medical Device Special Approval Procedure — all secured in August 2022. Wision A.I. goes to market through direct enterprise sales to hospitals, endoscopy centers, and pathology laboratories, with revenue structured around one-time medical-device software licensing rather than recurring subscription. The customer base is enterprise-clinical, segmented primarily by use case (gastroenterology/endoscopy versus histopathology), and the company maintains a modest operating footprint of 11–50 employees supported by a single disclosed $2.99M Series A from Northern Light Venture Capital in mid-2018.

Short descriptiontext

Wision A.I. is a Shanghai-based medical device company that develops regulatory-cleared deep-learning CAD software for gastrointestinal endoscopy (EndoScreener) and histopathology (PathoCruz), selling directly to hospitals and clinical laboratories via medical device licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
computer-aided diagnosis, medical imaging AI, colonoscopy detection, digital pathology, deep learning diagnostics
Industry3 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code1 code
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging AI Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Software Licensing
TypeOne Time License
Description

Wision A.I. generates revenue through the sale of regulatory-cleared AI-assisted diagnostic software medical devices. Their products (EndoScreener, PathoCruz) are cleared as medical devices in multiple jurisdictions (FDA, CE-MDR, NMPA), suggesting a medical device licensing model.

wision.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1EndoScreener
Description

Realtime AI-aided diagnostics product for gastrointestinal endoscopy procedures.

wision.com
+1 more record
Core offering1 text field

Wision A.I. develops and sells regulatory-cleared Computer-Aided Diagnosis (CAD) software for clinical optical medical imaging. Its core products—EndoScreener for real-time AI-assisted gastrointestinal endoscopy and colonoscopy, and PathoCruz for cancer region localization in whole slide histopathology images (plus the PathoCruz 3D reconstruction module)—are built on deep learning algorithms optimized for small datasets and are licensed to hospitals, endoscopy centers, and pathology laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First CE Mark Class II Certificate of CADe tools for colonoscopy under the new Medical Devices Regulation (MDR 2017/745)
Product overview1 text field

Wision A.I. offers a portfolio of Computer-Aided Diagnosis (CAD) products for clinical medical imaging. The core offerings consist of EndoScreener (real-time AI diagnostics for GI endoscopy/colonoscopy) and PathoCruz (histopathology whole slide image analysis). PathoCruz 3D is an add-on module that extends PathoCruz with 3D reconstruction capabilities for visualizing tumor spatial characteristics. All products leverage deep learning algorithms optimized for small datasets.

Product and service3 records
1EndoScreener
CategoryClinical Decision Support / GI Endoscopy AI
Description

Real-time AI-aided diagnostic software for gastrointestinal endoscopy procedures; provides computer-aided detection (CADe) during colonoscopy, automatically identifying and highlighting potential lesions, polyps, and adenomas. Regulatory-cleared as a medical device (FDA 510(k), CE-MDR Class II, NMPA Class III) and licensed to hospitals and endoscopy centers.

2PathoCruz
CategoryClinical Decision Support / Digital Pathology AI
Description

AI-powered whole slide imaging analysis software for histopathology; performs automated localization of cancerous regions and tumor areas in Whole Slide Images (WSI) to support pathologists in cancer diagnosis. Targets clinical pathology laboratories and hospital pathology departments.

3PathoCruz 3D
CategoryClinical Decision Support / Digital Pathology AI
Description

Automated histological 3D reconstruction module that visualizes tumor spatial characteristics from whole slide imaging data; extends the PathoCruz platform for advanced spatial tumor analysis by pathologists.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based startup developing AI-driven computer-aided detection (CADe) and computer-aided diagnosis (CADx) tools for gastroenterology, most notably for colonoscopy. Direct competitor to Wision's EndoScreener product line in the GI endoscopy AI space.

TypeBroad incumbent
Description

Global medical device giant that markets GI Genius, an AI colonoscopy CADe system acquired through its partnership with Cosmo Pharmaceuticals. Broad incumbent competitor offering Wision's primary GI endoscopy use case bundled into a vast medtech portfolio.

TypeDirect peer
Description

Specialty pharma company that developed the AI CADe engine (Medtronic GI Genius) for colonoscopy. Direct peer in the colonoscopy AI algorithm category competing with EndoScreener's core clinical application.

TypeBroad incumbent
Description

Dominant endoscope manufacturer increasingly integrating AI features (e.g., ENDO-AID) into its colonoscopy platforms. Broad incumbent that can bundle AI imaging with hardware, representing a structural threat to standalone CADe software players like Wision.

TypeDirect peer
Description

US-based digital pathology AI company with FDA-authorized cancer detection algorithms for whole slide imaging. Direct competitor to Wision's PathoCruz product line in AI-enabled cancer localization on histopathology slides.

TypeDirect peer
Description

Israel-based AI pathology company offering cancer detection and grading solutions for biopsy tissue across multiple tumor types. Direct peer to PathoCruz in the digital pathology AI market serving hospital pathology laboratories.

TypeEmerging player
Description

Digital pathology platform company offering AI-powered image analysis alongside its Concentriq pathology workflow software. Overlaps with Wision's PathoCruz at the intersection of AI image analysis and pathology lab workflow.

TypeEmerging player
Description

AI biotech company applying machine learning to pathology and clinical data across multiple oncology indications. Adjacent peer in medical imaging AI with overlapping pathology applications.

TypeEmerging player
Description

China-based medical imaging AI platform from Tencent covering endoscopy, pathology, and radiology applications. Direct regional competitor in China with overlapping GI endoscopy and digital pathology capabilities.

TypeBroad incumbent
Description

Major endoscopy and medical imaging OEM increasingly incorporating AI features into its colonoscopy and pathology workflows. Broad incumbent competitor whose installed base of endoscopes and pathology scanners gives it distribution leverage against standalone AI vendors like Wision.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wision A.I.

Medical Imaging AI Softwarewision.com

Wision A.I. is a Shanghai-based medical device company that develops regulatory-cleared deep-learning CAD software for gastrointestinal endoscopy (EndoScreener) and histopathology (PathoCruz), selling directly to hospitals and clinical laboratories via medical device licensing.

What Wision A.I. does

Wision A.I. is a Shanghai-based medical device software company founded in 2016 that develops computer-aided diagnosis (CAD) algorithms for optical clinical imaging, with a stated focus on solving diagnostic problems using small datasets rather than the prevailing big-data paradigm. Its commercial portfolio consists of two flagship products: EndoScreener, a real-time AI-aided detection (CADe) tool that flags potential lesions and polyps during colonoscopy, and PathoCruz, which localizes cancerous regions in whole-slide histopathology images; a 3D reconstruction add-on, PathoCruz 3D, extends the pathology line into tumor spatial visualization. Underlying both products is a deep-learning computer-vision pipeline with an articulated mathematical-rigor orientation toward limited training data.

The company monetizes as a regulated medical device vendor, not as a SaaS or platform play. Its products have been cleared as medical devices across the three principal regulatory regimes — FDA 510(k) (K211326), CE-MDR Class II (the first colonoscopy CADe clearance under MDR 2017/745), and NMPA Class III via China's Innovative Medical Device Special Approval Procedure — all secured in August 2022. Wision A.I. goes to market through direct enterprise sales to hospitals, endoscopy centers, and pathology laboratories, with revenue structured around one-time medical-device software licensing rather than recurring subscription. The customer base is enterprise-clinical, segmented primarily by use case (gastroenterology/endoscopy versus histopathology), and the company maintains a modest operating footprint of 11–50 employees supported by a single disclosed $2.99M Series A from Northern Light Venture Capital in mid-2018.

Wision A.I. firmographics

Firmographics
Name
Wision A.I.
Legal name
Wision A.I.
Website
https://wision.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Wision A.I. is a Shanghai-based medical device company that develops regulatory-cleared deep-learning CAD software for gastrointestinal endoscopy (EndoScreener) and histopathology (PathoCruz), selling directly to hospitals and clinical laboratories via medical device licensing.
Ownership category
akta.pro rank

Wision A.I. industry classification

Industry
Product category
Medical Imaging AI Software
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Computer-aided diagnosis
  • Medical imaging AI
  • Colonoscopy detection
  • Digital pathology
  • Deep learning diagnostics

Where Wision A.I. is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Markets served

Wision A.I. business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Medical Device Software Licensing: Wision A.I. generates revenue through the sale of regulatory-cleared AI-assisted diagnostic software medical devices. Their products (EndoScreener, PathoCruz) are cleared as medical devices in multiple jurisdictions (FDA, CE-MDR, NMPA), suggesting a medical device licensing model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Wision A.I. product offering

Product offering

Core offering

Wision A.I. develops and sells regulatory-cleared Computer-Aided Diagnosis (CAD) software for clinical optical medical imaging. Its core products—EndoScreener for real-time AI-assisted gastrointestinal endoscopy and colonoscopy, and PathoCruz for cancer region localization in whole slide histopathology images (plus the PathoCruz 3D reconstruction module)—are built on deep learning algorithms optimized for small datasets and are licensed to hospitals, endoscopy centers, and pathology laboratories.

Product overview

Wision A.I. offers a portfolio of Computer-Aided Diagnosis (CAD) products for clinical medical imaging. The core offerings consist of EndoScreener (real-time AI diagnostics for GI endoscopy/colonoscopy) and PathoCruz (histopathology whole slide image analysis). PathoCruz 3D is an add-on module that extends PathoCruz with 3D reconstruction capabilities for visualizing tumor spatial characteristics. All products leverage deep learning algorithms optimized for small datasets.

Differentiator

Problem solved

Functional benefit

Brands

  • EndoScreener: Realtime AI-aided diagnostics product for gastrointestinal endoscopy procedures.
  • PathoCruz

Products and services

  • EndoScreener Real-time AI-aided diagnostic software for gastrointestinal endoscopy procedures; provides computer-aided detection (CADe) during colonoscopy, automatically identifying and highlighting potential lesions, polyps, and adenomas. Regulatory-cleared as a medical device (FDA 510(k), CE-MDR Class II, NMPA Class III) and licensed to hospitals and endoscopy centers.
  • PathoCruz AI-powered whole slide imaging analysis software for histopathology; performs automated localization of cancerous regions and tumor areas in Whole Slide Images (WSI) to support pathologists in cancer diagnosis. Targets clinical pathology laboratories and hospital pathology departments.
  • PathoCruz 3D Automated histological 3D reconstruction module that visualizes tumor spatial characteristics from whole slide imaging data; extends the PathoCruz platform for advanced spatial tumor analysis by pathologists.

Quantifiable outcome

  • First CE Mark Class II Certificate of CADe tools for colonoscopy under the new Medical Devices Regulation (MDR 2017/745)

Companies that use Wision A.I.

Customer profile

Segments2 records

Ideal customer profiles2 records

Wision A.I. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Wision A.I. partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Wision A.I. competitors and assessment

Company assessment

Direct peers

  • Iterative Health: US-based startup developing AI-driven computer-aided detection (CADe) and computer-aided diagnosis (CADx) tools for gastroenterology, most notably for colonoscopy. Direct competitor to Wision's EndoScreener product line in the GI endoscopy AI space.
  • Cosmo Pharmaceuticals: Specialty pharma company that developed the AI CADe engine (Medtronic GI Genius) for colonoscopy. Direct peer in the colonoscopy AI algorithm category competing with EndoScreener's core clinical application.
  • Paige.AI: US-based digital pathology AI company with FDA-authorized cancer detection algorithms for whole slide imaging. Direct competitor to Wision's PathoCruz product line in AI-enabled cancer localization on histopathology slides.
  • Ibex Medical Analytics: Israel-based AI pathology company offering cancer detection and grading solutions for biopsy tissue across multiple tumor types. Direct peer to PathoCruz in the digital pathology AI market serving hospital pathology laboratories.

Broad incumbents

  • Medtronic (GI Genius): Global medical device giant that markets GI Genius, an AI colonoscopy CADe system acquired through its partnership with Cosmo Pharmaceuticals. Broad incumbent competitor offering Wision's primary GI endoscopy use case bundled into a vast medtech portfolio.
  • Olympus: Dominant endoscope manufacturer increasingly integrating AI features (e.g., ENDO-AID) into its colonoscopy platforms. Broad incumbent that can bundle AI imaging with hardware, representing a structural threat to standalone CADe software players like Wision.
  • Fujifilm: Major endoscopy and medical imaging OEM increasingly incorporating AI features into its colonoscopy and pathology workflows. Broad incumbent competitor whose installed base of endoscopes and pathology scanners gives it distribution leverage against standalone AI vendors like Wision.

Emerging players

  • Proscia: Digital pathology platform company offering AI-powered image analysis alongside its Concentriq pathology workflow software. Overlaps with Wision's PathoCruz at the intersection of AI image analysis and pathology lab workflow.
  • Owkin: AI biotech company applying machine learning to pathology and clinical data across multiple oncology indications. Adjacent peer in medical imaging AI with overlapping pathology applications.
  • Tencent Miying: China-based medical imaging AI platform from Tencent covering endoscopy, pathology, and radiology applications. Direct regional competitor in China with overlapping GI endoscopy and digital pathology capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Wision A.I. social profiles

Digital presence

Wision A.I. compliance and trust

Trust signal

Compliance3 records

Wision A.I. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wision A.I. leadership team

Management profile

Number of profiles

Profiles2 records

Wision A.I. funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wision A.I. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wision A.I.

What does Wision A.I. do?

Wision A.I. develops and sells regulatory-cleared Computer-Aided Diagnosis (CAD) software for clinical optical medical imaging. Its core products—EndoScreener for real-time AI-assisted gastrointestinal endoscopy and colonoscopy, and PathoCruz for cancer region localization in whole slide histopathology images (plus the PathoCruz 3D reconstruction module)—are built on deep learning algorithms optimized for small datasets and are licensed to hospitals, endoscopy centers, and pathology laboratories.

Is Wision A.I. a public or private company?

Wision A.I. is a private company. It is classified as venture growth investor backed and is currently operating.

When was Wision A.I. founded?

Wision A.I. was founded in 2016. It employs 1 to 10 people.

Where is Wision A.I. based?

Wision A.I. is headquartered in Shanghai, China, in the Asia region.

How does Wision A.I. make money?

One revenue line is on record: medical Device Software Licensing.

Who are Wision A.I.'s main competitors?

Direct peers on record are Iterative Health, Cosmo Pharmaceuticals, Paige.AI and Ibex Medical Analytics. Broad incumbents are Medtronic (GI Genius), Olympus and Fujifilm. Emerging players are Proscia, Owkin and Tencent Miying.

Does Wision A.I. have an API?

No public API is recorded for Wision A.I..

What industry is Wision A.I. in?

Wision A.I.'s product category is Medical Imaging AI Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 3345 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalAI in clinical practice: positive outcomes dominate but questions linger, study findsA scoping review of 84 randomized controlled trials on AI in clinical practice found 69 positive outcomes across primary endpoints. Most trials were gastroenterology-related and single-site, with the US leading. The authors call for multi-center trials with clinically meaningful endpoints.BioSpaceMicro-Tech Endoscopy Partners with Wision A.I. to Distribute its AI-assisted Polyp Detection Software in the U.S.Micro-Tech Endoscopy USA announced a partnership with Wision A.I. to distribute EndoScreener, an AI-assisted polyp detection software for colonoscopy, in the U.S. The software, FDA-cleared in November 2021, identified about 32% more adenomas than standard colonoscopy. Micro-Tech will be the only GI endoscopy distributor of the technology in the U.S.Vox3 ways AI is already changing medicineDr. Eric Topol's book Deep Medicine outlines three AI applications in medicine: automated eye and colon diagnostics, avatars for anxiety and depression, and AI to free up doctors' time. He argues AI will enhance rather than replace doctors, citing AI's 94% accuracy in diagnosing eye diseases and 29% polyp detection. He notes data privacy hurdles remain.Daily Medical NewsAI colonoscopy system may detect clues physicians ‘not tuned in to recognize’An AI colonoscopy system for automatic polyp detection increased adenoma detection rate from 20.3% to 29.1% in a trial of 1,058 patients. The system also raised detection of diminutive adenomas from 102 to 185 and hyperplastic polyps from 52 to 114. The author noted future interest in improving detection of sessile polyps in the right colon.CBS NewsArtificial intelligence could help doctors identify hard-to-spot colon polypsA patient underwent an AI-assisted colonoscopy at NYU Langone Health, where the computer detected a subtle flat polyp. A study in Nature Biomedical Engineering found AI detected polyps over 90% of the time. The polyps were benign, and the study is ongoing.BioSpaceWision AI Applies Expertise in Machine-Learning and Mathematical Medicine to Improve Polyp Detection during ColonoscopyWision AI announced a study validating a machine-learning algorithm that improves adenomatous polyp detection during colonoscopy. The algorithm achieved 94.4% per-image sensitivity and 95.9% specificity on a large independent dataset. The company plans to apply this technology in clinical trials.